Posted by Michael Wonder on 03 May 2022
VBI Vaccines announces European Commission marketing authorisation for PreHevbri, a 3 antigen adult hepatitis B vaccine
2 May 2022 - Regulatory review in the United Kingdom is on-going as part of the European Commission Decision Reliance Procedure.
VBI Vaccines today announced that the European Commission has granted Marketing Authorisation for PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults.
